Asset Details
Do you wish to reserve the book?
Palbociclib-Induced Interstitial Lung Disease in Metastatic Breast Cancer: A Case Report and Clinical Considerations
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Palbociclib-Induced Interstitial Lung Disease in Metastatic Breast Cancer: A Case Report and Clinical Considerations
Do you wish to request the book?
Palbociclib-Induced Interstitial Lung Disease in Metastatic Breast Cancer: A Case Report and Clinical Considerations
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Palbociclib-Induced Interstitial Lung Disease in Metastatic Breast Cancer: A Case Report and Clinical Considerations
2025
Overview
AbstractIntroduction: The treatment landscape of hormone receptor-positive, HER2-negative (HR+/HER2–) metastatic breast cancer (BC) has been transformed with the advent of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). While myelosuppression is the most common adverse effect, interstitial lung disease (ILD) has emerged as a rare but potentially severe complication in real-world settings. Case Presentation: A 76-year-old woman with metastatic HR+/HER2– BC developed ILD after approximately 20 months of palbociclib therapy. Treatment discontinuation and high-dose corticosteroids resulted in symptomatic and radiological improvement. A concomitant pneumomediastinum was considered a secondary manifestation of ILD. Conclusion: ILD is an underrecognized but clinically significant toxicity of CDK4/6i, requiring early diagnosis and prompt intervention to prevent severe respiratory compromise. A high index of clinical suspicion, prompt diagnosis, and rapid treatment strategies are crucial, particularly in elderly patients, to minimize ILD-associated risks and complications. Further research is needed to establish predictive biomarkers and optimize management guidelines for CDK4/6i-induced ILD.
Publisher
S. Karger AG,Karger Publishers
Subject
